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Abstract 
 
Improved Survival with Initial MRSA Therapy in High-Risk 
Community-Onset Pneumonia Patients: Application of a MRSA 
Risk Score 
 
Besu Fekad Teshome, M.S.P.S. 
The University of Texas at Austin, 2014 
 
Supervisor:  Christopher R. Frei 
 
Community-onset (CO) methicillin-resistant Staphylococcus aureus 
(MRSA) pneumonia is an evolving problem, and there is a great need for a 
reliable method to assess MRSA risk at hospital admission. A new MRSA 
prediction score classifies CO-pneumonia patients into low, medium, and high-
risk groups based on objective criteria available at baseline. Our objective was to 
assess the effect of initial MRSA therapy on mortality in these three risk groups. 
We conducted a retrospective cohort study using data from the Veterans 
Health Administration. Patients were included if they were hospitalized with 
pneumonia and received antibiotics within the first 48 hours of admission. They 
were stratified into MRSA therapy and no MRSA therapy treatment arms based 
  vii 
on antibiotics received in the first 48 hours. MRSA risk groups were analyzed 
separately. The primary outcome was 30-day patient mortality. Multivariable 
logistic regression was used to adjust for potential confounders.  
A total of 80,330 patients met inclusion criteria, of which 36% received 
MRSA therapy and 64% did not receive MRSA therapy. The majority of patients 
were classified as either low (51%) or medium (47%) risk, with only 2% classified 
as high-risk. In the high-risk group, unadjusted 30-day mortality was lower among 
patients who received initial MRSA therapy (40% versus 58%; p<0.0001). 
Likewise, multivariable logistic regression analysis also demonstrated that initial 
MRSA therapy was associated with a lower 30-day mortality in the high-risk 
group (adjusted odds ratio 0.57; 95% confidence interval 0.42-0.77). There was 
no benefit of initial MRSA therapy in the low or medium-risk groups. 
This study demonstrated improved survival with initial MRSA therapy in 
high-risk CO-pneumonia patients. The MRSA risk score should not replace 
clinical judgment, but it might be a useful tool to spare MRSA therapy for only 
those patients who are most likely to benefit.  
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CHAPTER ONE 
Introduction 
CO-MRSA Pneumonia 
 Pneumonia is a major cause of mortality in the United States, with a 
reported 49,597 deaths in 2010.1 Community-onset (CO) pneumonia is defined 
as pneumonia that occurs in the community and up to 48 hours into hospital 
admission. It encompasses both community-acquired pneumonia (CAP) and 
healthcare-associated pneumonia (HCAP). HCAP patients are defined as those 
CO-pneumonia patients with one or more of the following risk factors: 
hospitalization for ≥2 days in the past 90 days, residence in a nursing home or 
long-term care facility, recent home infusion or wound care, chronic dialysis, or 
family member with a multidrug-resistant (MDR) pathogen. Importantly, HCAP 
patients are at increased risk of methicillin-resistant Staphylococcus aureus 
(MRSA) pneumonia.2,3 Lastly, MRSA pneumonia is associated with greater 
morbidity and mortality than pneumonia caused by other etiologies, possibly due 
to the virulent and resistant nature of the MRSA pathogen.3 MRSA accounts for 
20% to 40% of pneumonia cases that occur after 48 hours into hospital 
admission and 2% to 25% of CO cases overall.3-7  
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HCAP Criteria Guiding Empiric MRSA Therapy 
Previous studies have demonstrated that rapid initiation of appropriate 
antibiotic therapy is associated with improved survival in hospitalized patients 
with infections;8,9 therefore, there is a great need for a reliable method to assess 
CO-MRSA pneumonia risk at hospital admission. Guidelines recommend use of 
the HCAP criteria to determine need for empiric MRSA therapy, but this definition 
lacks specificity for CO-MRSA pneumonia and may lead to overuse of broad-
spectrum antibiotic therapy.2,10 Furthermore, prior studies have demonstrated 
that when HCAP patients received guideline-recommended, broad-spectrum 
therapy (including MRSA therapy), outcomes were no better than when similar 
patients received alternative antibiotics.11,12  
 
HCAP Inappropriate for CO-MRSA Pneumonia 
HCAP criteria assume that the risk factors for MRSA and gram-negative 
MDR pathogens are identical, and therefore recommend broad-spectrum 
antibiotics, including MRSA therapy, for all HCAP patients. This approach lacks 
specificity for CO-MRSA. CO-MRSA pneumonia has its own distinct risk factors 
that differ from gram-negative MDR risk factors; therefore, the HCAP criteria 
might be inadequate to determine which patients should receive empiric MRSA 
therapy.13-15 Furthermore, there are several reports of severe CO-MRSA 
pneumonia from strains arising solely from the community and causing infection 
in patients without HCAP risk factors.16-20 In this case, the HCAP criteria might 
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lack sensitivity for CO-MRSA. Guidelines have since been published regarding 
empiric therapy for CO-MRSA pneumonia in certain patients; however, these 
recommendations are mostly based on case studies and expert opinion.21,22 
 
MRSA Risk Score  
Guidance is needed for clinicians to identify those CO-pneumonia patients 
that might benefit from empiric MRSA therapy. Recently, Shorr et al. derived a 
clinical prediction score that stratified patients with CO-pneumonia by their MRSA 
risk.23 The total score ranged from 0 to 10, and patients were stratified into low 
(0-1), medium (2-5), and high (6-10) risk groups. The CO-MRSA pneumonia 
prevalence increased from <10% in the low-risk group to >30% in the high-risk 
group. The authors concluded that this risk score could help identify those 
patients at low risk of MRSA, for which MRSA therapy could be spared. They 
postulated that patients in the high-risk group might benefit from MRSA 
therapy;23 however, this has yet to be proven. A similar claim was made for the 
HCAP criteria;2,4 yet, follow-up studies have failed to show a survival benefit with 
the broad-spectrum therapies recommended by the HCAP guidelines as 
compared to alternative therapies.11,12 
 
MRSA Risk Score Requires Application 
The new MRSA risk score could help guide empiric MRSA therapy; 
however, studies are needed to determine which, if any, of the MRSA risk groups 
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benefit from such therapy. Our primary objective was to compare the effect of 
MRSA therapy on 30-day patient mortality among CO-pneumonia patients in the 
three MRSA risk groups (low, medium, and high-risk). 
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CHAPTER TWO 
Methods 
Study Design 
This study used administrative data from the Veterans Health 
Administration (VHA) database. Description of the methods used to build this 
database have been previously reported.11,24,25 In brief, we performed a 
retrospective, population-based cohort study using administrative data from the 
VHA system between fiscal years 2002 and 2007. These data are from over 150 
VHA hospitals and 850 VHA outpatient clinics. Data for this study were obtained 
from the VHA electronic medical record system that includes administrative, 
clinical, laboratory, and pharmacy data. 
 
Patient Eligibility 
Patients were included if they were ≥65 years of age and had either a 
primary discharge diagnosis of pneumonia/influenza (International Classification 
of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 480.0–
483.99 or 485–487) (Table 1) or a secondary discharge diagnosis of 
pneumonia/influenza plus a primary diagnosis of respiratory failure (ICD-9-CM 
code 518.81), or sepsis (ICD-9-CM code 038.xx) in fiscal years 2002 to 2007. If a 
patient was admitted more than once during the study period, only the first 
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hospitalization was included. Patients were excluded if they did not receive 
antimicrobial therapy within the first 48 hours of admission.  
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Table 1. ICD-9-CM Codes for Patient Variables and Bacterial Pathogens 
Variable ICD-9-CM Codes 
Hemodialysis 403.01, 403.11, 403.91, 404.02, 404.12, 404.92, 
404.93, 584, 585, 586 
Invasive mechanical ventilation 96.7 
Non-invasive mechanical ventilation 93.90, 93.91 
Comorbid conditions 
     Dementia 290 
     Myocardial infarction 410, 412 
     Congestive heart failure 428 
     Cerebrovascular disease 430-438 
     COPD 490-496, 500-505, 506.4 
     Liver disease 571.2, 571.4, 571.5, 571.6, 572.2-572.8, 456.0-
456.21 
     Diabetes  250.0-250.3, 250.4, 250.5, 250.6, 250.7, 250.8, 
250.9 
     Renal disease  582, 583, 585, 586, 588 
     Neoplastic disease 140-172, 174-208 
     HIV/AIDS 42-44, V08 
Organ failure 
     Respiratory 518.81, 518.82, 518.85, 518.89, 786.09, 799.1, 
96.7 
     Cardiovascular 458.0, 458.8, 458.9, 785.5, 796.3 
     Neurologic 293, 348, 348.3, 780.01, 780.09, 89.14 
     Renal 580, 584, 585, 039.95 
     Hematologic 286.2, 286.6, 286.9, 287.3, 287.4, 287.5 
     Hepatic 570, 572.2, 573.3 
Bacterial Pneumonia Pathogens 
     Streptococcus pneumoniae 481 
     Streptococcus, other 482.30, 482.31, 482.32, 482.40 
     Staphylococcus, unspecified 482.40 
     Staphylococcus aureus 482.41 
     MRSA V09.0 
     Klebsiella pneumoniae 482.0 
     Pseudomonas spp. 482.1 
     Haemophilus influenzae 482.2 
     Escherichia coli  482.82 
     Other gram-negative bacteria 482.83 
     Legionella spp. 482.84 
     Mycoplasma pneumoniae 483.0 
     Chlamydia spp. 483.1 
     Anaerobes 482.81 
COPD: chronic obstructive pulmonary disease; HIV/AIDS: human immunodeficiency virus 
/acquired immunodeficiency syndrome; MRSA: methicillin-resistant Staphylococcus aureus 
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Baseline Characteristics 
Baseline demographics and comorbid conditions were recorded at the 
time of admission. Antibiotic use was recorded for the first 48 hours of admission. 
Race was recorded for “white” or “black” patients. Native Americans, Hawaiians, 
and those with missing race information were stratified into an “other” category. 
Ethnicity was reported for patients who identified themselves as Hispanic. 
Comorbid conditions were determined using ICD-9-CM codes from outpatient 
and inpatient care in accordance with the Charlson comorbidity scoring 
system.26,27 Medication use within 90 days of admission was identified for 
cardiovascular medications, anti-diabetic medications, inhaled and systemic 
corticosteroids, and pulmonary medications using electronic inpatient and 
outpatient medical records (Table 2). Finally, patients with hemodialysis, organ 
failure, and those requiring mechanical ventilation (invasive or non-invasive) 
were also identified using ICD-9-CM codes. 
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Table 2. List Of Medications Used Within 90 Days Of Admission, By Class 
Drug Class Medications 
Cardiovascular 
medications 
Aliskiren, ambrisentan, amiloride, amlodipine, atenolol, 
atorvastatin, benazepril, bendroflumethizide, bepridil, 
betaxolol, bisoprolol, bretylium, bumetanide, carteolol, 
carvedilol, chlorothiazide, chlorthalidone, clevidipine, 
clonidine, diazoxide, digoxin, diltiazem, disopyramide, 
dofetilide, doxazosin, eplerenone, epoprostenol, esmolol, 
ethacrynic acid, felodipine, fenoldopam, flecainide, 
furosemide, guanabenz, guanadrel, guanethidine, 
guanfacine, hydralazine, hydrochlorothiazide, ibutilide, 
iloprost, inamrinone, indapamide, isosorbide, isoxsuprine, 
isradipine, labetalol, mannitol, mecamylamine, 
methyclothiazide, methyldopa, metolazone, metoprolol, 
metyrosine, mexiletine, milrinone, minoxidil, moricizine, 
nadolol, nebivolol, nesiritide, nicardipine, nifedipine, 
nimodipine, nisoldipine, nitroglycerin, papaverine, 
penbutolol, perindopril, phentolamine, pindolol, polythiazide, 
prazosin, procainamide, propafenone, propranolol, 
quinidine, reserpine, sotalol, spironolactone, terazosin, 
timolol, tocainidine, tolazoline, torsemide, treprostinil, 
triamterene, trimethaphan, verapamil 
Antidiabetic medications Acarbose, chlorpropamide, exenatide, glimepiride, glipizide, 
glyburide, insulin, metformin, miglitol, nateglinide, 
pioglitazone, pramlintide, repaglinide, rosiglitazone, 
sitagliptin, tolazamide, tolbutamide 
Inhaled corticosteroids Flunisolide, fluticasone, mometasone, triamcinolone 
Systemic corticosteroids Betamethasone, budesonide, cortisone, dexamethasone, 
hydrocortisone, methylprednisolone, prednisolone, 
prednisone, triamcinolone 
Pulmonary medications  Acetylcysteine, albuterol, aminophylline, arformoterol, 
beractant, bitolterol, caffeine, calfactant, cetyl alcohol, 
ciclesonide, colfosceril, cromolyn, dornase alfa, doxapram, 
formoterol, ipratropium, levalbuterol, metaproterenol, 
montelukast, nedocromil, nitric oxide, omalizumab, 
pirbuterol, poractant alfa, salmeterol, terbutaline, 
theophylline, tobramycin, tyloxapol, zafirlukast, zileuton 
 
  
  10 
MRSA Risk Score 
The MRSA risk score variables were defined as: patient age >79 years, 
hospitalization in the past 90 days, intensive care unit (ICU) admission, 
outpatient intravenous (IV) antibiotic therapy within the past 90 days, nursing 
home resident in the last 90 days, cerebrovascular disease, dementia, and 
female with diabetes mellitus. These were based on the MRSA risk score 
developed by Shorr et al. and modified for our database. All of our patients were 
≥65 years of age, so the criteria related to age <30 years did not apply. Also, 
recent hospitalization was not limited to stays of ≥2 days, prior IV antibiotic 
therapy was extended from 30 to 90 days, and ICU admission was not limited to 
on or before index culture.23 Each variable contributed one point to the risk score, 
except for hospitalization in the past 90 days and ICU admission, for which each 
contributed two points. Patients were stratified into three risk groups based on 
their risk score: low (0-1), medium (2-5), and high (6-10).23 
 
Antibiotic Therapy and Pathogens 
Patients who met study criteria were divided into two groups: the “MRSA 
therapy” group and the “no MRSA therapy” group. Initial MRSA therapy was 
defined as the receipt of either vancomycin or linezolid within the first 48 hours of 
admission. Patients were also categorized based on the receipt of guideline-
concordant community-acquired pneumonia (GC-CAP) therapy,21 pseudomonal 
therapy, and atypical therapy (Table 3). Pneumonia pathogens were identified 
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using ICD-9-CM codes: Streptococcus pneumoniae, Streptococcus other, 
Staphylococcus aureus, MRSA, Klebsiella pneumoniae, Pseudomonas spp., 
Escherichia coli, Haemophilus influenzae, other Gram-negative pathogens, 
Mycoplasma pneumoniae, Legionella spp., Chlamydia spp., and anaerobes 
(Table 1).  
 
Table 3. Antibiotic Therapy Definitions 
MRSA therapy  
• Vancomycin 
• Linezolid 
Guideline-Concordant CAP therapy 
Ward patients 
• Beta-lactam1 plus (macrolide or 
doxycycline) 
• Respiratory fluoroquinolone2 
ICU patients 
• Beta-lactam1 plus (macrolide or 
doxycycline) 
• Beta-lactam1 plus respiratory 
fluoroquinolone2 
Pseudomonal therapy 
• Antipseudomonal beta-lactam3 plus antipseudomonal fluoroquinolone4 
• Antipseudomonal beta-lactam3 plus aminoglycoside5 
Atypical therapy 
• Macrolide 
• Doxycycline  
• Any fluoroquinolone 
CAP: community-acquired pneumonia; ICU: intensive care unit 
Macrolide includes azithromycin, clarithromycin, or erythromycin 
1Beta-lactam includes cefotaxime, ceftriaxone, ampicillin-sulbactam, ertapenem, or 
aztreonam  
2Respiratory fluoroquinolone includes moxifloxacin, levofloxacin, or gatifloxacin 
3Antipseudomonal beta-lactam includes cefepime, ceftazidime, imipenem-cilastatin, 
meropenem, piperacillin-tazobactam, or ticarcillin-clavulanate, aztreonam 
4Antipseudomonal fluoroquinolone includes ciprofloxacin or levofloxacin 
5Aminoglycoside includes gentamicin, tobramycin, or amikacin 
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Primary Study Outcome 
All-cause 30-day patient mortality was the primary study outcome. 
Previous research has demonstrated that 30-day mortality is more closely 
associated with pneumonia-related mortality, as compared to 60-day or 90-day 
mortality.28 Mortality was assessed using the VHA vital status file, which has 
been demonstrated to have 98% exact agreement with the National Death Index, 
the “gold standard” to determine mortality.29  
 
Statistical Analyses 
All statistical analyses were conducted using JMP 10.0® (SAS Corp, Cary, 
NC). Chi-square or Fisher’s exact test were used to compare categorical 
variables between patients who received MRSA therapy and did not receive 
MRSA therapy (Table 4). Continuous variables were compared using the 
Wilcoxon Rank Sum test (Table 4). For bivariate statistical tests, we defined 
significance as a two-tailed alpha ≤0.0001 to avoid spurious associations in this 
large patient cohort. 
Separate multivariable logistic regression models were constructed to 
examine if MRSA therapy was associated with 30-day mortality in the overall 
population and each of the three MRSA risk groups. The dependent variable was 
30-day patient mortality, and the independent variable was MRSA therapy versus 
no MRSA therapy. Covariates included all unbalanced characteristics from table 
4. Because the dependent variable in the multivariable model was 30-day 
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mortality, baseline characteristics that were significant in the bivariate analysis 
comparing 30-day mortality versus no 30-day mortality were also included as 
covariates in the multivariable models (Table 5). Finally, MRSA culture-positivity 
was also entered into the model.  
A few of the variables were then excluded from the model because of 
collinearity. For instance, most patients on hemodialysis also had renal failure; 
therefore, renal failure was chosen for the model. Likewise, most patients who 
had diabetes mellitus also received anti-diabetic medications; therefore, anti-
diabetic medications was chosen for the model. The Charlson score and the “any 
organ failure” variables were excluded from the model because individual 
comorbidities and organ failures were already included in the model. Individual 
MRSA risk score variables were also excluded from the model because we ran 
separate multivariable models for the three risk groups, and these individual 
characteristics were used to define those risk groups. 
The final list of 25 covariates included: patient age, race, Hispanic 
ethnicity, myocardial infarction, heart failure, chronic obstructive pulmonary 
disease (COPD), liver disease, renal disease, neoplastic disease, cardiovascular 
medications, anti-diabetic medications, inhaled corticosteroids, pulmonary 
medications, vasopressors, invasive and non-invasive mechanical ventilation, 
respiratory failure, cardiovascular failure, neurological failure, renal failure, 
hematological failure, hepatic failure, GC-CAP therapy, pseudomonal therapy, 
atypical therapy, and MRSA culture-positivity.  
  14 
Adjusted odds ratios (aORs) and 95% confidence intervals (95% CI) were 
calculated; those 95% CI that did not cross one were considered to be 
statistically significant. This was done for the overall population and each of the 
three risk groups. 
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Table 4. Baseline Characteristics Grouped by MRSA Therapy 
 Overall 
(n=80,330) 
MRSA 
therapy 
(n=29,254) 
No MRSA 
therapy 
(n=51,076) 
P-value 
Patient age (years), median (IQR) 78 (72-83) 78 (73-83) 77 (72-83) 0.1016 
Male, %  98.3 98.3 98.3 0.6847 
Race, % 
     White 81.1 79.1 82.3 <0.0001 
     Black 13.1 15.4 11.7 <0.0001 
     Other 5.8 5.5 6.0 <0.0001 
Hispanic ethnicity, % 7.0 8.0 6.4 <0.0001 
MRSA risk score variables, % (1 point, unless noted) 
     Age >79 43.8 44.0 43.7 0.3867 
     Hospitalization in the past 90 days (2 points) 27.8 33.7 24.5 <0.0001 
     Intensive care unit admission (2 points) 21.1 29.3 16.4 <0.0001 
     Outpatient IV antibiotic therapy in past 90 days 4.9 5.3 4.7 0.0001 
     Nursing home resident in last 90 days 1.0 1.1 0.9 0.0028 
     Cerebrovascular disease 18.1 19.6 17.3 <0.0001 
     Dementia 5.2 5.8 4.9 <0.0001 
     Female with diabetes mellitus 0.4 0.4 0.4 0.8129 
MRSA risk score, median (IQR) 1 (0-3) 2 (1-3) 1 (0-2) <0.0001 
     Low (0-1), % 51.4 41.6 57.0 <0.0001 
     Medium (2-5), % 47.3 56.4 42.1 <0.0001 
     High (6-10), % 1.3 2.1 0.9 <0.0001 
Charlson comorbidity score, median (IQR) 2 (1-4) 3 (1-4) 2 (1-4) <0.0001 
Comorbid conditions, % 
     Myocardial infarction 7.2 7.6 7.0 0.0020 
     Heart failure 25.9 27.0 25.3 <0.0001 
     Chronic obstructive pulmonary disease 48.7 45.5 50.5 <0.0001 
     Liver disease 1.3 1.5 1.2 0.0035 
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Table 4, cont. 
     Renal disease 14.1 17.2 12.3 <0.0001 
     Diabetes 30.5 31.8 29.8 <0.0001 
     Neoplastic disease 25.2 26.2 24.7 <0.0001 
     HIV/AIDS 0.2 0.3 0.2 0.0961 
Medication use within 90 days, % 
     Cardiovascular medications 66.5 64.9 67.3 <0.0001 
     Anti-diabetic medications 22.2 22.6 22.1 0.0852 
     Inhaled corticosteroids 21.1 18.9 22.4 <0.0001 
     Systemic corticosteroids γ 22.2 21.8 22.5 0.0217 
     Pulmonary medications 34.8 31.4 36.8 <0.0001 
Vasopressors, % 10.2 15.2 7.2 <0.0001 
Invasive mechanical ventilation, % 11.1 16.3 8.2 <0.0001 
Noninvasive mechanical ventilation, % 4.0 5.7 3.1 <0.0001 
Hemodialysis, % 18.3 22.7 15.7 <0.0001 
Organ failure, % 
     Any organ failure, % 32.2 41.8 26.7 <0.0001 
          Respiratory 14.4 19.4 11.5 <0.0001 
          Cardiovascular 9.7 13.0 7.8 <0.0001 
          Neurological 2.5 3.3 2.0 <0.0001 
          Renal 20.1 26.8 16.2 <0.0001 
          Hematologic 4.1 5.5 3.3 <0.0001 
          Hepatic 0.7 0.9 0.6 <0.0001 
Antibiotic therapy, % 
     Guideline-concordant CAP therapy 64.1 64.9 63.6 0.0001 
     Pseudomonal therapy 17.5 31.1 9.7 <0.0001 
     Atypical therapy 75.2 83.6 70.5 <0.0001 
MRSA: methicillin-resistant Staphylococcus aureus; IQR: interquartile range; IV: intravenous; HIV/AIDS: human 
immunodeficiency virus / acquired immunodeficiency syndrome:  
γ Includes oral and/or injectable corticosteroids; CAP: community-acquired pneumonia 
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Table 5. Baseline Characteristics Grouped by 30-Day Patient Mortality 
 Overall 
(n=80,330) 
30-day 
mortality 
(n=15,909) 
No 30-day 
mortality 
(n=64,421) 
P-value 
Patient age (years), median (IQR) 78 (72-83) 79 (74-84) 77 (72-82) <0.0001 
Male, % 98.3 98.5 98.2 0.0100 
Race, % 
     White 81.1 77.3 82.0 <0.0001 
     Black 13.1 14.9 12.6 <0.0001 
     Other 5.8 7.8 5.3 <0.0001 
Hispanic ethnicity, % 7.0 7.9 6.8 <0.0001 
MRSA risk score variables, % (1 point, unless noted) 
     Age >79 43.8 51.0 42.0 <0.0001 
     Hospitalization in the past 90 days (2 points) 27.8 40.7 24.7 <0.0001 
     Intensive care unit admission (2 points) 21.1 42.0 16.0 <0.0001 
     Outpatient IV antibiotic therapy in past 90 days 4.9 6.0 4.7 <0.0001 
     Nursing home resident in last 90 days 1.0 0.8 1.0 0.0292 
     Cerebrovascular disease 18.1 20.0 17.7 <0.0001 
     Dementia 5.2 6.7 4.9 <0.0001 
     Female with diabetes mellitus 0.4 0.4 0.4 0.8881 
MRSA risk score, median (IQR) 1 (0-3) 2 (1-2) 1 (0-2) <0.0001 
     Low (0-1), % 51.4 28.4 57.1 <0.0001 
     Medium (2-5), % 47.3 68.4 42.1 <0.0001 
     High (6-10), % 1.3 3.25 0.9 <0.0001 
Charlson comorbidity score, median (IQR) 2 (1-4) 3 (1-5) 2 (1-4) <0.0001 
Comorbid conditions, % 
     Myocardial infarction 7.3 8.7 6.9 <0.0001 
     Heart failure 25.9 28.2 25.4 <0.0001 
     Chronic obstructive pulmonary disease 48.7 41.7 50.4 <0.0001 
     Liver disease 1.3 2.3 1.1 <0.0001 
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Table 5, cont.  
     Renal disease 14.1 16.7 13.4 <0.0001 
     Diabetes 30.5 30.3 30.5 0.5493 
     Neoplastic disease 25.2 31.1 23.8 <0.0001 
     HIV/AIDS 0.2 0.2 0.2 0.2145 
Medication use within 90 days, % 
     Cardiovascular medications 66.5 60.0 68.0 <0.0001 
     Anti-diabetic medications 22.2 20.0 22.8 <0.0001 
     Inhaled corticosteroids 21.1 14.8 22.7 <0.0001 
     Systemic corticosteroids γ 22.2 21.1 22.5 0.0002 
     Pulmonary medications 34.8 27.8 36.6 <0.0001 
Vasopressors, % 10.2 26.9 6.0 <0.0001 
Invasive mechanical ventilation, % 11.1 26.8 7.3 <0.0001 
Noninvasive mechanical ventilation, % 4.0 7.1 3.3 <0.0001 
Hemodialysis, % 18.3 23.5 17.0 <0.0001 
Organ failure, % 
     Any organ failure, % 32.2 57.8 25.9 <0.0001 
          Respiratory 14.4 32.6 9.9 <0.0001 
          Cardiovascular 9.7 22.1 6.7 <0.0001 
          Neurological 2.5 4.2 2.0 <0.0001 
          Renal 20.1 35.3 16.3 <0.0001 
          Hematologic 4.1 8.3 3.0 <0.0001 
          Hepatic 0.7 2.0 0.3 <0.0001 
Antibiotic therapy, % 
     MRSA therapy 36.4 42.9 34.8 <0.0001 
     Guideline-concordant CAP therapy 64.1 38.6 70.4 <0.0001 
     Pseudomonal therapy 17.5 23.8 15.9 <0.0001 
     Atypical therapy 75.2 54.3 80.4 <0.0001 
MRSA: methicillin-resistant Staphylococcus aureus; IQR: interquartile range; IV: intravenous; HIV/AIDS: human immunodeficiency 
virus/acquired immunodeficiency syndrome 
γ Includes oral and/or injectable corticosteroids; CAP: community-acquired pneumonia 
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CHAPTER THREE 
Results 
Overall Population 
Baseline patient characteristics are shown in table 4. A total of 80,330 
patients met inclusion criteria, with 36% in the MRSA therapy group and 64% in 
the no MRSA therapy group. Patients were predominately elderly (median age 
78 years), white (81%) men (98%). Age >79 was the most common MRSA risk 
factor (44%), followed by hospitalization in the past 90 days (28%) and ICU 
admission (21%). There were very few women with diabetes mellitus (0.4%) in 
this population. The median MRSA risk score was 1 (interquartile range [IQR] 0–
3). The majority of patients were classified as either low (51%) or medium (47%) 
risk, with only 2% classified as high-risk. None of the patients scored above an 8 
on the MRSA risk score.  
The median (IQR) Charlson score was 2 (1-4), and common comorbidities 
included COPD (49%), diabetes (31%), heart failure (26%), and neoplastic 
disease (25%). The most commonly used medications within 90 days prior to 
admission included cardiovascular medications (67%) and pulmonary 
medications (35%). Organ failure occurred in 32% of patients. Finally, most 
patients received atypical (75%) and GC-CAP (64%) therapy. 
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Baseline Characteristics: MRSA Therapy vs. No MRSA Therapy  
 Patient age and sex were similar between MRSA therapy and no MRSA 
therapy groups. A lower proportion of white patients received MRSA therapy 
(79% versus 82%), while higher proportions of black (15% versus 12%) and 
Hispanic (8% versus 6%) patients received MRSA therapy (all p<0.0001).  
Among the MRSA risk factors, patients who received MRSA therapy had 
higher rates of hospitalization in the past 90 days (34% versus 25%), ICU 
admission (29% versus 16%), outpatient IV antibiotic therapy in the past 90 days 
(5.3% versus 4.7%), cerebrovascular disease (20% versus 17%), and dementia 
(6% versus 5%) (all p<0.0001). The proportions of patients with age >79 years, 
nursing home residence in the last 90 days, and women with diabetes mellitus 
were similar between groups.  
Patients in the MRSA therapy group had higher MRSA risk scores 
compared to those in the no MRSA therapy group (median [IQR] 2 [1–3] versus 1 
[0–2]; p<0.0001). Those in the MRSA therapy group were also more likely to be 
assigned to the medium (56% versus 42%) and high-risk (2% versus 1%) 
groups, whereas they were less likely to be assigned to the low-risk group (42% 
versus 57%) (all p<0.0001).  
Charlson scores were higher in the MRSA therapy group (median [IQR] 3 
[1–4] versus 2 [1–4]; p<0.0001) and these patients had a higher prevalence of 
heart failure, renal disease, diabetes, and neoplastic disease (all p<0.0001). In 
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addition, the MRSA therapy group had a higher prevalence of vasopressor use, 
mechanical ventilation, hemodialysis, organ failure, GC-CAP therapy, 
pseudomonal therapy, and atypical therapy (all p≤0.0001). In contrast, the no 
MRSA therapy group had a higher prevalence of COPD and were more likely to 
receive cardiovascular medications, inhaled corticosteroids, and pulmonary 
medications in the last 90 days (all p<0.0001) 
 
Bacterial Pathogens 
The prevalence of bacterial pathogens is shown in table 6. 
Staphylococcus aureus was the most commonly isolated pathogen and the 
majority of those isolates were MRSA. Streptococcus pneumoniae was the 
second most common pathogen. The MRSA therapy group had more patients 
who were culture-positive and had higher rates of Staphylococcus aureus, 
MRSA, Pseudomonas spp., and most other gram-negative pathogens except for 
Haemophilus influenzae.  
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Table 6. Bacterial Pathogen Distribution Grouped by MRSA Therapy 
 Overall 
(n=80,330) 
MRSA therapy 
(n=29,254) 
No MRSA 
therapy 
(n=51,076) 
P-value 
Organism identified, % 10.3 13.9 8.2 <0.0001 
     Single organism identified 9.3 12.1 7.7 <0.0001 
     Multiple organisms identified 1.0 1.9 0.5 <0.0001 
Gram-positive pathogens, % 
     Streptococcus pneumoniae 2.8 2.7 2.9 0.0571 
     Streptococcus, other 0.4 0.5 0.4 0.0270 
     Staphylococcus aureus 5.1 8.7 3.1 <0.0001 
     MRSA 3.3 5.1 2.3 <0.0001 
Gram-negative pathogens, % 
     Klebsiella pneumoniae 0.7 1.0 0.6 <0.0001 
     Pseudomonas spp. 1.5 1.9 1.2 <0.0001 
     Haemophilus influenzae 0.8 0.5 0.9 <0.0001 
     Escherichia coli 0.2 0.4 0.2 <0.0001 
     Other gram-negatives 0.5 0.6 0.4 0.0007 
Atypical pathogens, % 
     Mycoplasma pneumoniae < 0.1 < 0.1 0.1 0.0839 
     Legionella spp. 0.1 0.2 0.1 0.2029 
     Chlamydia spp. < 0.1 < 0.1 < 0.1 0.7561 
Anaerobes, % 0.1 0.1 0.1 0.0139 
 MRSA: methicillin-resistant Staphylococcus aureus 
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Patient Mortality 
The overall 30-day patient mortality rate was 20%, and the unadjusted 30-
day mortality increased from the low (11%), medium (27%), and high (48%) risk 
groups (p<0.0001). In the overall population, MRSA therapy was associated with 
a higher unadjusted 30-day mortality compared to the no MRSA therapy group 
(23% versus 18%; p<0.0001). Unadjusted 30-day mortality was higher among 
patients who received MRSA therapy in the low-risk group (15% versus 9%; 
p<0.0001), but lower in the high-risk group (40% versus 58%; p<0.0001), as 
compared to those who did not receive MRSA therapy (Figure 1). In addition, an 
increase in unadjusted 30-day mortality was observed with each additional point 
of the MRSA risk score (Figure 2). After adjustment for potential confounders, 
MRSA therapy was associated with higher 30-day mortality in the low-risk group 
(aOR 1.47; 95% CI 1.37-1.58) and lower 30-day mortality in the high-risk group 
(aOR 0.57; 95% CI 0.42-0.77) (Figure 1) 
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Figure 1. 30-Day Patient Mortality by MRSA Risk Group and MRSA Therapy 
 
aOR: Adjusted Odds Ratio; 95% CI: 95% Confidence Interval; MRSA: methicillin-resistant Staphylococcus aureus 
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      Figure 2. Unadjusted 30-Day Patient Mortality by MRSA Risk Score 
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Mortality Risk Factors 
The multivariable regression analysis revealed several variables that were 
independently associated with 30-day mortality (Table 7). The strongest 
independent predictors of 30-day mortality in the overall population were hepatic 
failure (aOR 2.54; 95% CI 2.08-3.11) and respiratory failure (aOR 2.48; 95% CI 
2.34-2.63). Other independent risk factors for 30-day mortality included 
increasing patient age, myocardial infarction, heart failure, liver disease, use of 
vasopressors, mechanical ventilation, any type of organ failure, and 
pseudomonal therapy. Cardiovascular medications, anti-diabetic medications, 
inhaled corticosteroids, GC-CAP therapy, and atypical therapy were associated 
with greater 30-day survival. Risk factors varied for low, medium, and high-risk 
groups (Table 7). 
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      Table 7. Risk Factors for 30-Day Patient Mortality Grouped by MRSA Risk Score 
 Adjusted Odds ratio (95% confidence interval) 
Risk score All (n= 80,330) 0-1 (n=41,282) 2-5 (n=37,975) 6-10 (n=1,073) 
MRSA therapy 1.22 (1.17-1.27) 1.47 (1.37-1.58) 1.05 (1.00-1.11) 0.57 (0.42-0.77) 
Age (1-year increments) 1.05 (1.04-1.05) 1.05 (1.05-1.06) 1.04 (1.03-1.04) 1.05 (1.02-1.08) 
Race 0.99 (0.94-1.05) 0.95 (0.86-1.06) 0.98 (0.91-1.05) 1.18 (0.85-1.64) 
Hispanic ethnicity 0.85 (0.79-0.92) 0.84 (0.73-0.96) 0.86 (0.79-0.95) 0.79 (0.47-1.32) 
Comorbid conditions  
     Myocardial infarction 1.14 (1.06-1.23) 1.11 (0.94-1.30) 1.05 (0.97-1.14) 1.06 (0.74-1.51) 
     Heart failure 1.16 (1.11-1.21) 1.07 (0.97-1.17) 1.11 (1.05-1.18) 1.16 (0.88-1.53) 
     COPD 0.96 (0.91-1.00) 0.92 (0.85-1.00) 0.95 (0.89-1.01) 1.30 (0.96-1.77) 
     Liver disease 1.79 (1.54-2.08) 1.34 (0.97-1.87) 1.80 (1.50-2.14) 3.46 (1.08-13.51) 
     Renal disease 0.98 (0.93-1.04) 0.91 (0.81-1.02) 0.96 (0.90-1.03) 1.12 (0.83-1.53) 
     Neoplastic disease 1.54 (1.47-1.60) 1.57 (1.46-1.69) 1.48 (1.40-1.56) 1.18 (0.87-1.59) 
Medication use, by class 
     Cardiovascular medications 0.72 (0.69-0.75) 0.60 (0.56-0.64) 0.78 (0.73-0.82) 0.91 (0.66-1.24) 
     Anti-diabetic medications 0.92 (0.87-0.96) 0.78 (0.71-0.86) 0.95 (0.90-1.01) 0.95 (0.70-1.29) 
     Inhaled corticosteroids 0.76 (0.72-0.81) 0.73 (0.65-0.81) 0.80 (0.74-0.86) 1.13 (0.77-1.65) 
     Pulmonary medications 1.00 (0.94-1.05) 0.93 (0.85-1.03) 1.03 (0.97-1.11) 0.68 (0.48-0.97) 
Vasopressors 1.81 (1.70-1.93) 3.00 (2.49-3.61) 1.66 (1.55-1.79) 1.52 (1.12-2.04) 
Mechanical ventilation 
     Invasive  1.08 (1.01-1.16) 2.48 (1.98-3.10) 1.02 (0.95-1.10) 0.92 (0.65-1.29) 
     Noninvasive 1.16 (1.06-1.27) 2.03 (1.60-2.57) 1.03 (0.94-1.13) 1.22 (0.80-1.86) 
Organ failure 
     Respiratory 2.48 (2.34-2.63) 3.84 (3.45-4.29) 2.03 (1.90-2.18) 1.47 (1.06-2.04) 
     Cardiovascular 1.91 (1.80-2.02) 1.90 (1.68-2.15) 1.81 (1.69-1.94) 1.36 (1.02-1.82) 
     Neurological 1.53 (1.38-1.71) 1.64 (1.33-2.02) 1.40 (1.23-1.58) 1.92 (1.03-3.65) 
     Renal 1.58 (1.51-1.66) 1.77 (1.62-1.94) 1.46 (1.38-1.55) 1.15 (0.87-1.51) 
     Hematologic 1.65 (1.52-1.80) 1.97 (1.67-2.32) 1.53 (1.39-1.69) 1.18 (0.73-1.90) 
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      Table 7, cont. 
     Hepatic 2.54 (2.08-3.11) 3.21 (2.05-5.00) 2.38 (1.90-2.99) 0.66 (0.20-2.16) 
Antibiotic therapy 
     GC-CAP therapy 0.67 (0.63-0.70) 0.60 (0.54-0.67) 0.73 (0.69-0.79) 0.73 (0.50-1.08) 
     Pseudomonal therapy 1.25 (1.19-1.32) 1.68 (1.53-1.85) 1.05 (0.99-1.12) 0.76 (0.54-1.06) 
     Atypical therapy 0.45 (0.43-0.48) 0.59 (0.53-0.66) 0.46 (0.43-0.49) 0.75 (0.52-1.08) 
MRSA 0.66 (0.59-0.74) 0.58 (0.45-0.73) 0.66 (0.58-0.75) 0.56 (0.31-0.99) 
Bold indicates statistical significance; MRSA: methicillin-resistant Staphylococcus aureus; Race was ordered as black 
versus nonblack; COPD: Chronic obstructive pulmonary disease; GC-CAP: guideline-concordant community-acquired 
pneumonia 
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CHAPTER FOUR 
 
Discussion 
Summary 
 CO-MRSA pneumonia is an evolving problem, and clinicians need 
strategies to determine appropriate candidates for empiric MRSA therapy. Shorr 
et al. developed a risk score to specifically identify CO-pneumonia patients at risk 
for MRSA infection.23 Using a MRSA risk score similar to Shorr et al., our study 
demonstrates a survival advantage for CO-pneumonia among high-risk patients 
who received initial MRSA therapy. This survival advantage was not present for 
patients in the low and medium-risk groups. 
 
Clinical Implications 
 Our study supports the notion that the MRSA risk score might be a better 
alternative to guide empiric MRSA therapy in patients with CO-pneumonia as 
compared to the HCAP criteria. Several studies have demonstrated that the 
HCAP criteria have low specificity for MRSA pneumonia, and that grouping risk 
factors for MRSA with other gram-negative MDR pathogens may lead to 
inappropriate treatment.10,13,30-32 Recently, Chalmers et al. conducted a meta-
analysis of 24 studies that compared HCAP and CAP cohorts. The study 
concluded that the ability for the HCAP criteria to appropriately identify patients 
with MDR pathogens (including MRSA) was low and did not meet the threshold 
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for clinical use.33 In addition, most studies evaluating the utility of HCAP criteria 
to guide broad-spectrum therapy, including MRSA therapy, have not 
demonstrated improved mortality with guideline-concordant therapy.11,12   
One advantage of the MRSA risk score is weighting of important risk 
factors. The MRSA risk score assigns more weight (2 points each) to patients 
with recent hospitalization and severe pneumonia requiring ICU admission 
compared to the other risk factors (1 point each). In a recent study stratifying risk 
factors for MDR pathogens in CO-pneumonia patients, recent hospitalization and 
severe pneumonia were found to be independent predictors of mortality.34 This 
highlights a key feature of the MRSA risk score, because patients with either of 
those two risk factors cannot be classified into the low-risk group. Recently, 
Minejima et al. compared a smaller cohort of CO-pneumonia patients with 
culture-proven MRSA pneumonia and non-MRSA pneumonia. They found 37% 
of patients with non-MRSA pneumonia met HCAP criteria and 28% received 
unnecessary MRSA therapy. Had the MRSA risk score been applied, 
unwarranted MRSA therapy could have been decreased by 20% in low-risk 
patients without MRSA pneumonia.35 Our findings further support the idea that 
the new MRSA risk score can help identify low-risk CO-pneumonia patients who 
are unlikely to benefit from empiric MRSA therapy. 
Our data also demonstrate the utility of the MRSA risk score to identify 
high-risk patients that are likely to benefit from initial MRSA therapy. CO-MRSA 
pneumonia has been associated with mortality rates of 22% to 51% among 
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inpatients.3,19,36 In our study, patients stratified to the low-risk group had an 
overall 30-day mortality of 11%, which is similar to mortality rates in CAP patients 
from previous studies.4-6 In contrast, patients in the high-risk group had the 
highest overall 30-day mortality at 48%, which is within the range of mortality 
rates previously reported for CO-MRSA pneumonia.3,19,36 Importantly, 30-day 
mortality was decreased by 18% in our high-risk patients who received initial 
MRSA therapy as compared to those who did not receive initial MRSA therapy. 
The number needed to treat with initial MRSA therapy to save one life in the 
high-risk group was 5. 
Notably, there are distinct differences between our study population and 
the study cohort used by Shorr et al. to derive the MRSA risk score. Our study 
included both culture-positive and culture-negative patients in the cohort, 
whereas the study by Shorr et al. was limited to culture-positive patients. We 
believe that our study population might be more generalizable because clinicians 
frequently do not know the pneumonia etiology at admission, if ever. CO-
pneumonia studies using exclusively culture-positive cohorts tend to report 
higher MRSA prevalence (14% to 25%) compared to studies that include both 
culture-positive and culture negative-patients (2% to 3%).4-7 This may help 
explain the difference in the overall MRSA prevalence between Shorr et al. and 
our study (14% versus 3%).23 Culture-positive HCAP patients have been shown 
to have increased rates of ICU admission and mortality compared to culture-
negative patients;37 however, the majority of CO-pneumonia patients are culture-
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negative, and clinicians often have to initiate antimicrobial therapy before 
obtaining culture data.21 The inclusion of both culture-positive and culture-
negative patients in our study allows for data that more closely resemble real-life 
situations. We used the MRSA risk score in a manner similar to widely accepted 
severity-of-illness scores (i.e., CURB-65), and we were able to demonstrate its 
utility for this purpose.  
 
Limitations 
 While our study provides valuable data regarding the management of CO-
MRSA pneumonia patients, it has some important limitations. First, several 
studies have identified risk factors associated with CO-MRSA pneumonia that 
were not included in the MRSA risk score. These include: MRSA infection in the 
past year, known MRSA colonization, necrotizing or cavitary pneumonia, 
severity-of-illness scores, and preceding or concurrent influenza.15-22,35 Clinicians 
should utilize individual patient characteristics to help them in the decision to 
initiate MRSA therapy among all risk groups, especially those that fall into the 
medium-risk group where the benefit of initial MRSA therapy was inconclusive. 
Second, the data source included mostly males and only contained patients ≥65 
years of age, limiting the generalizability of the results. This brings to light some 
inherent limitations of the risk score and its ability to be applied in various 
populations. Nevertheless, our results demonstrate the risk score still retains its 
clinical utility despite use of a population different from that which the risk score 
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was derived. We also attempted to account for potential confounders by using 
multivariable logistic regression models; however, this might not control for 
confounding by unmeasured variables. Lastly, the retrospective nature of our 
study and reliance on ICD-9-CM codes can possibly lead to confounding and 
misclassification bias.  
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CHAPTER FIVE 
Conclusions 
 
This study demonstrated the clinical utility of the MRSA risk score for CO-
pneumonia patients by showing that 30-day mortality is lower in high-risk patients 
who receive initial MRSA therapy; however, this positive effect on mortality was 
not present in the low and medium-risk groups. The MRSA risk score should not 
replace clinical judgment, but it may be a useful tool to identify patients who do 
and do not warrant empiric MRSA therapy. 
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